Devyser CFTR achieves IVDR compliance, strengthening clinical confidence in cystic fibrosis diagnostics
Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...
Read More
With the IVDR transition approaching, European clinical laboratories are preparing for changes that...
Read More
The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...
Read More
RhD incompatibility remains a critical concern in prenatal care, with the potential to cause...
Read More